rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NVO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Novo Nordisk: The Worst May Be Behind

      Novo Nordisk is rated a long-term Buy, as falling capital spending supports higher free cash flow, with a DKK 393.21 intrinsic value.

      10h agoSeeking AlphaNVO
      Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance

      Four-year renewed commitment will help advance the development of much-needed products to prevent, diagnose, and treat dangerous bacterial infectionsHELLERUP, Denmark and BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- The Novo Nordisk Foundation and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced the renewal of their partnership to accelerate the development of an integrated portfolio of innovative products to address bacterial infections and antimicrobi

      21h agoYahoo FinanceNVO
      Novo Nordisk (NVO) Could Be 47% Below Fair Value Following Its AI Push
      21h agoYahoo FinanceNVO
      Novo Nordisk: The Thesis Is Working, The Stock Just Hasn't Noticed Yet

      Analyst maintains a Strong Buy rating on Novo Nordisk at 10.89x non-GAAP earnings as free cash flow guidance rises to DKK 60–70 billion.

      Nov 17Seeking AlphaNVO
      Nine riders with type 1 diabetes turn professional with Team Novo in 2027
      Nov 17Yahoo FinanceNVO
      Danes Are Crooning Over Novo Despite Drugmaker’s Share Slump
      Nov 17BloombergNVO
      Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops
      Nov 17BenzingaNVO
      Novo Nordisk expands Novocare program for Wegovy users
      Nov 17Investing.comNVO
      Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue | The Motley Fool

      Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump.

      Nov 17The Motley FoolNVO
      The serious complications of GLP-1s that few may know about

      With millions of patients taking GLP-1 drugs, doctors are discovering rare but worrying problems affecting the body and the mind.

      Nov 16The Washington PostNVO
      Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival
      Nov 16BarchartAMGNNVO
      Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision
      Nov 16BenzingaNVO
      Six-year-olds: Novo’s new frontier for weight-loss drugs
      Nov 16Financial TimesNVO
      Novo Nordisk stock rises on CagriSema weight loss data
      Nov 16Investing.comNVO
      Novo Nordisk A/S - share repurchase programme
      Nov 16Yahoo FinanceNVO
      Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval

      The Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.

      Nov 16WSJNVO
      Novo Nordisk (CPSE:NOVO B) Scores Phase 3 Win And EU Approval Across New Therapies

      Novo Nordisk (CPSE:NOVO B) reported positive phase 3 results for its investigational obesity therapy CagriSema, supporting a future filing plan. The company received European Union approval for haemophilia A treatment FREHEMGO, with a launch planned in initial EU markets in 2026. Regulatory submissions for sickle cell disease therapy etavopivat were filed with both the US Food and Drug Administration and the European Medicines Agency. These CagriSema, FREHEMGO and etavopivat updates come...

      Nov 16Yahoo FinanceNVO
      Novo Nordisk Shares Gain 2.4% Following Additional CagriSema Weight-Loss Trial Analyses
      Nov 16Yahoo FinanceNVO
      Why is Novo Nordisk stock climbing today?
      Nov 16Investing.comNVO
      Novo Nordisk reports additional CagriSema weight-loss findings

      Novo Nordisk's exploratory CagriSema analyses found 25.4% weight loss among early responders by week 68; a U.S.

      Nov 15Seeking AlphaNVO
      Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026
      Nov 15Yahoo FinanceNVO
      Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
      Nov 14ReutersLLYNVO
      Makers of obesity drugs hit back at claims of negative side effects
      Nov 14Financial TimesLLYNVO
      Novo Nordisk Scores EU Win For Hemophilia Drug, Advances Sickle Cell Treatment Toward Approval
      Nov 13BenzingaNVO
      Novo's haemophilia drug gets EU approval
      Nov 13ReutersNVO
      FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
      Nov 13Yahoo FinanceNVO
      Novo Nordisk Submits Sickle Cell Disease Treatment Etavopivat for US and European Regulatory Approval
      Nov 13Yahoo FinanceNVO
      Novo Nordisk Seeks FDA, EMA Approval For Sickle Cell Disease Treatment – Here Are The Key Takeaways
      Nov 13Yahoo FinanceNVO
      Novo Nordisk (CPSE:NOVO B) Taps DJ Khaled As Oral Weight Loss Race Heats Up

      Novo Nordisk (CPSE:NOVO B) has partnered with DJ Khaled to promote his Wegovy weight loss journey to a wider US audience. Eli Lilly has received the first Chinese regulatory approval for an oral GLP-1 weight loss pill, ahead of Novo Nordisk's own oral product. Novo Nordisk's obesity portfolio now faces a fresh test as Wegovy promotion coincides with Eli Lilly's oral GLP-1 approval in China. Check out 3 other big wins that Novo Nordisk investors should know about. For a broader view on how...

      Nov 13Yahoo FinanceNVO
      Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval
      Nov 13Yahoo FinanceNVO
      No more needles: Eli Lilly wins China nod for first oral GLP-1 weight-loss drug
      Nov 13South China Morning PostLLYNVO
      Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval
      Nov 12Yahoo FinanceNVO
      Novo Nordisk partners with DJ Khaled for Wegovy campaign
      Nov 12Investing.comNVO
      Novo Nordisk Stock: Better Than It Looks, But Not A Buy Yet (NYSE:NVO)

      Novo Nordisk's future hinges on broadening its drug franchises, notably CagriSema and Zenagamtide. Read why NVO stock is a hold.

      Nov 12Seeking AlphaNVO
      China approves Eli Lilly's GLP-1 weight-loss pill, giving it lead over Novo - report (LLY:NYSE)
      Nov 12Seeking AlphaLLYNVO
      Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China
      Nov 12ReutersLLYNVO
      Novo Nordisk: Valuations Are Blind To The Upside (NYSE:NVO)

      Novo Nordisk's Q3 2026 beat and overlooked guidance upgrades make medium-term de-rating exceedingly unlikely. Click for more on the NVO stock.

      Nov 11Seeking AlphaNVO
      Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady
      Nov 11Yahoo FinanceHIMSLLYNVO
      Novo commits $200 million to the World Diabetes Foundation
      Nov 11ReutersNVO
      Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care
      Nov 11Yahoo FinanceNVO
      Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady
      Nov 10Yahoo FinanceHIMSLLYNVO
      Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

      The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.

      Nov 10BBCNVO
      Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
      Nov 10Yahoo FinanceNVO
      Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

      GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment

      Nov 10The GuardianNVO
      What Does Novo Nordisk (CPSE:NOVO B) FDA Vision Warning Mean For Investors?
      Nov 10Yahoo FinanceNVO
      FDA tells GLP-1 makers to warn of potential vision loss side effect

      The agency is requiring GLP-1 manufacturers to warn the drugs can increase risk of “eye stroke.”

      Nov 10The Washington PostNVO
      Novo Resources Releases Updated Corporate Presentation

      PERTH, Australia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp.  (Novo or the Company ) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is please...

      Nov 9Business InsiderNVO
      FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness

      GLP-1 drugs may increase the risk of NAION, a rare optic nerve condition that can lead to sudden vision loss and has no known treatment.

      Nov 9NBC NewsLLYNVO
      Eli Lilly, Novo weight-loss drugs to get rare vision loss warning (LLY:NYSE)
      Nov 9Seeking AlphaLLYNVO
      Eli Lilly’s Weight-Loss Pill Shows Sleep Apnea Benefits. Can It Gain on Novo?
      Nov 9Barron'sLLYNVO

      This is the newest page. Registered accounts read further back.